Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.
CAS Registry Number
14047-41-7
Molecular formula
C14H18N3O10-5
Molecular weight
388.31 g/mol
Drug class
Pentetic acid (DTPA)metal chelator and decorporation agent
Mechanism of action
Forms stable complexes with selected trivalent and divalent metal ions, including plutonium, americium and curium, promoting their excretion in urine. Calcium-DTPA and zinc-DTPA are the authorised decorporation salts; the free acid is not interchangeable by dose.
Indications / reported uses
Treatment to enhance elimination of internal contamination with plutonium, americium or curium following known or suspected radioactive contamination, using the appropriate calcium-DTPA or zinc-DTPA formulation under specialist radiation-emergency guidance
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope
Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
Phase I exposure screening and trigger evaluation.
Environmental fate and ecotoxicity review, with Phase II work where required.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope
Environmental Risk Assessment (ERA)
ReguSight provides project-specific support for the Diethylenetriaminepentaacetate Environmental Risk Assessment (ERA) (the Diethylenetriaminepentaacetate ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
Product, active-substance identity, formulation, route and intended-market review.
Phase I environmental exposure screening and applicable trigger evaluation.
Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
Data-gap analysis, study strategy, assumptions and scientific reporting.
The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.